Sep 24 |
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
|
Sep 17 |
MaxCyte and Kamau Therapeutics sign platform license agreement
|
Sep 16 |
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
|
Sep 5 |
MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
|
Aug 21 |
MaxCyte (LON:MXCT) shareholders have earned a 22% CAGR over the last five years
|
Aug 7 |
MaxCyte, Inc. (MXCT) Q2 2024 Earnings Call Transcript
|
Aug 6 |
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
|
Aug 6 |
MaxCyte GAAP EPS of -$0.09 beats by $0.04, revenue of $10.4M beats by $2.47M
|
Aug 6 |
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
|
Jul 17 |
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
|